mRNA Vaccines Market (2026-2036)

The growth of this market is mainly driven by the speed and adaptability of the mRNA platform, the expansion of approved mRNA vaccines beyond COVID-19 into RSV and next-generation formulations, the advancement of individualized mRNA cancer vaccines, and international partnerships and regional manufacturing investments. However, the sharp post-pandemic decline in COVID-19 vaccine demand, the reversal of U.S. government funding and narrower vaccine recommendations, safety perceptions and vaccine hesitancy, and manufacturing overcapacity and inventory losses restrain the growth of this market.

Furthermore, individualized neoantigen cancer vaccines, combination respiratory vaccines, and self-amplifying mRNA are expected to offer growth opportunities for the stakeholders in this market. However, intellectual property disputes, clinical setbacks and durability questions, competition from alternative vaccine platforms, and fragmented national recommendations and reimbursement remain major challenges impacting the growth of this market. Additionally, the transition from a pandemic to a seasonal and oncology market, cost restructuring and consolidation, next-generation formulations with improved stability and lower doses, and geographic diversification and onshore manufacturing are prominent trends in this market.

The mRNA Vaccines Market comprises vaccines that deliver messenger RNA encoding one or more antigens, typically formulated in lipid nanoparticles, instructing the body's cells to produce the antigen and stimulate a protective or therapeutic immune response. The market covers prophylactic vaccines against infectious diseases, including COVID-19, respiratory syncytial virus, influenza, combination respiratory vaccines, cytomegalovirus and other latent viruses, and emerging and pandemic threats, and therapeutic vaccines, primarily individualized neoantigen and shared-antigen cancer vaccines. It spans conventional non-replicating mRNA using modified nucleosides, self-amplifying mRNA, which encodes replication machinery to amplify the antigen-encoding RNA inside cells, and emerging circular and other next-generation RNA technologies. Market value is measured at manufacturer sales of approved vaccines, including government procurement. mRNA-based protein replacement and gene editing therapeutics are excluded. The ecosystem spans mRNA vaccine developers, lipid nanoparticle and nucleotide technology providers, contract development and manufacturing organizations, raw material suppliers, governments and public health agencies, pharmacies, clinics, oncology centers, and regulators.

The mRNA platform achieved historic success during the COVID-19 pandemic, when Pfizer and BioNTech's Comirnaty and Moderna's Spikevax were the first vaccines to receive U.S. emergency use authorization in December 2020, and the underlying nucleoside-modification science was recognized with the 2023 Nobel Prize in Physiology or Medicine. Comirnaty sales peaked at USD 37.8 billion in 2022 and Spikevax at USD 18.44 billion, before declining sharply as the pandemic ended, the U.S. public health emergency was declared over in May 2023, and U.S. vaccines moved to commercial sales in September 2023. Comirnaty sales fell to USD 5.35 billion in 2024, Moderna's product sales fell to USD 3.08 billion in 2024, and Moderna's total revenue fell further to USD 1.9 billion in 2025, with fourth-quarter revenue of USD 678 million, down 30%, and inventory write-downs of USD 144 million in the quarter.

The market is transitioning to a seasonal and multi-indication model. Moderna now has three approved products, Spikevax, the next-generation COVID-19 vaccine mNEXSPIKE, and the RSV vaccine mRESVIA, received approvals for mNEXSPIKE in Canada and Australia, signed long-term respiratory vaccine agreements with Mexico and Taiwan, and guided up to 10% revenue growth for 2026 after reducing annual operating expenses by about USD 2.2 billion. Self-amplifying mRNA has also reached the market, with Arcturus and CSL's Kostaive approved in Japan in 2023 and the EU in 2025, and individualized mRNA cancer vaccines, such as Moderna and Merck & Co.'s intismeran autogene and BioNTech's autogene cevumeran, are in late-stage development. BioNTech's acquisition of CureVac in 2025 has consolidated mRNA expertise and intellectual property.

At the same time, policy headwinds have intensified. In August 2025, the U.S. Department of Health and Human Services began winding down 22 mRNA vaccine development projects funded by BARDA, worth about USD 500 million, stating that it would shift funding toward other vaccine platforms, and U.S. regulators and advisory bodies narrowed COVID-19 vaccine approvals and recommendations in 2025 to focus on older adults and people at higher risk. Vaccine hesitancy, intellectual property disputes, and competition from other platforms add to the challenges, while the platform's speed and adaptability, its role in pandemic preparedness, and its potential in oncology support long-term growth.